24/7 Wall Street
10 Jul 2026, 19:37 UTC · 2h ago
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
10 Jul 2026, 19:37 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Ionis Pharmaceuticals' Phase 3 CARDIO-TTRansform study of eplontersen failed to meet its primary efficacy endpoint for ATTR-CM. — The failure of a key value driver in a Phase 3 trial directly led to a 21% weekly drop in stock price.
-0.90Alnylam Pharmaceuticals' Amvuttra and BridgeBio's Attruby face reduced near-term competitive pressure following the eplontersen miss. — A competitor's failure in the same therapeutic area typically increases the market share potential for remaining viable drugs.
+0.40Ionis has three upcoming catalysts: full ESC trial data in August, a PDUFA for Alexander disease on September 22, and a hepatitis B decision on October 26. — These regulatory and data milestones provide the only immediate paths for stock recovery or further devaluation.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Arrowhead Pharmaceuticals and Sarepta Therapeutics saw share price declines due to sector sympathy despite unrelated business operations. — This indicates a general risk-off sentiment toward RNA-targeted drug developers following the Ionis news.
-0.20Which stocks this story touches
Shares plummeted after a Phase 3 clinical trial for eplontersen failed to meet its primary efficacy endpoint.
The stock fell due to sector sympathy despite having an unrelated business.
Shares declined in line with the general downturn in the RNA and rare-disease biotech sector.
Partnered with Ionis on the failed Phase 3 CARDIO-TTRansform study.
Despite a price dip, analysts view its product as a direct beneficiary of a competitor's clinical failure.
The stock bucked the general sector selloff and traded slightly higher.
Mentioned only as a comparison point for a private company investment opportunity.
[mutual] Ionis and AstraZeneca are partners in the Phase 3 CARDIO-TTRansform study of eplontersen.
[mutual] Alnylam's Amvuttra competes directly with Ionis's eplontersen in ATTR-CM.
[mutual] Biogen is a collaborator that co-develops multiple antisense assets with Ionis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
10h ago
